breast-cancer-summit-2017-posters-accepted-abstracts

11 / 20

Page 48
conferenceseries.com
Volume 2, Issue 2 (Suppl) Breast Can Curr Res
ISSN: 2572-4118 BCCR, an open access journal Breast Cancer Summit 2017
May 08-10, 2017
May 08-10, 2017 Singapore
4th World Congress on
Breast Cancer
Expression of D2-40 in benign and malignant breast lesions and study the correlation between
lymphovascular density and other prognostic factors of breast cancer
Hala Abdeldayem Mouhamed1 and Afaf Taha Ibrahiem 2
1Suez Canal University, Egypt
2Mansoura University, Egypt
Background: D2-40 is a mouse monoclonal antibody specific for human podoplanin and has been used in identifying lymphovascular
invasion (LVI) of tumors also its expression has been used as a marker for myoepithelial cells (MEC) of breast. Lymphangiogenesis,
assessed as lymphovascular density (LVD), is the initial step of generalized tumor lymphovascular invasion (LVI). It also involves
VEGF-Cas themost important protein family. Lymphangiogenesis amongbreast cancer cases correlateswithseveral clinicopathological
factors are important to determine prognosis and treatment strategies, but results have been controversial and require clarification.
Aim: The aim of this work is to explore the expression of D2-40 as a marker for myoepithelial cells (MECs) of the breast lesions, to
investigate the clinicopathological significance of VEGF-C, D2-40 expression and lymphovascular density (LVD) in breast cancer
patients.
Methods: Sections from 88 paraffin-embedded archival specimens of breast lesions were selected to include benign breast lesions as
fibrocystic changes of the breast and ductal hyperplasia (15 cases) and invasive breast cancer (73 cases). Immunohistochemistry (IHC)
for D2-40, calponin and VEFG-C were performed and IHC staining results and the associations of intratumoral and peritumoral
LVD were correlated with clinicopathologi¬cal features and prognosis were assessed.
Results: D2-40 highlighted the MECs of benign breast lesions beside its identified lymphatic vessels and LVI in breast carcinomas.
VEGF-C expression was significantly higher in invasive breast cancer than benign breast lesions (p<0.01). VEGF-C (p <0.001)
expression was significantly associated with peritumoral LVD, but not intratumoral LVD. VEGF-C expression, peritumoral LVD and
LVI were significantly associated with lymph node metastasis (p=0.025, p=0.006 and p =0.017, respectively). Moreover, peritumoral
LVD was an independent risk factor for axillary lymph node metastasis, disease-free survival in multivariate analysis.
Conclusions: Our results show that D2-40 is a reliable marker highlights MECs in benign breast lesions beside it is a useful tool for
identification of LVI in breast carcinomas which is reflecting a potential for lymphatic metastatic spread and possible poor prognosis.
Our study also demonstrated that high expression of VEGF-C in invasive breast carcinoma may induce lymphangiogenesis in the
peritumoral area. Peritumoral LVD appeared to be a potential independent prognostic factor in breast cancer patients.
Hala Abdeldayem Mouhamed, Breast Can Curr Res 2017, 2:2(Suppl)